Novavax INC Form 4 insider transactions

Novavax Director Charles W. Newton acquired 9,520 shares of common stock through the vesting of restricted stock units.

Novavax EVP of R&D Robert Walker was granted 99,500 stock options and 66,000 restricted stock units on April 14, 2026.

Novavax's EVP, CFO, and Treasurer, James Patrick Kelly, reported the vesting of 43,167 Restricted Stock Units and a subsequent sale of 20,850 shares to cover tax obligations.

Novavax President and CEO, John C. Jacobs, reported the vesting of 150,167 Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Novavax's Chief Strategy Officer, Elaine O'Hara, acquired common stock through RSU vesting and sold shares for tax obligations, increasing her direct beneficial ownership.

Novavax's EVP, Chief Legal Officer, Mark J. Casey, increased his direct common stock ownership by 26,122 shares after RSU vesting and tax withholding, with an additional 4,000 RSUs vesting.

Novavax CEO John C. Jacobs reported significant equity awards, including new Restricted Stock Units and stock options, alongside the vesting and tax-related disposition of existing shares.

Novavax's EVP, CFO, and Treasurer, James Patrick Kelly, reported significant equity transactions including RSU vesting, tax-related share disposals, and new grants of RSUs and stock options.

Novavax's Chief Strategy Officer, Elaine O'Hara, reported the vesting and acquisition of restricted stock units and a new grant of stock options.

Novavax's EVP, Chief Legal Officer, Mark J. Casey, reported recent equity transactions including RSU vesting, tax-related share disposals, and new RSU and stock option grants.

Novavax President and CEO John C. Jacobs reported exercising restricted stock units and subsequently selling a portion of the acquired common stock to cover tax obligations.

Novavax's EVP, Chief Legal Officer Mark J Casey, exercised 41,899 Restricted Stock Units and subsequently sold 12,713 shares for tax withholding.

Novavax officer Ruxandra Draghia-Akli acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.

Novavax Director Richard J. Rodgers converted 3,800 Restricted Stock Units into common stock, increasing his direct beneficial ownership.

Novavax, Inc. (NVAX) Director Richard J. Rodgers was granted 28,326 stock options and 18,884 restricted stock units as part of his compensation.

Novavax Inc. Director David M. Mott has acquired 28,326 stock options and 18,884 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Novavax Inc. Director Rachel K. King was granted 28,326 stock options and 18,884 restricted stock units, aligning her interests with shareholders.

Novavax Inc. Director Richard Douglas was granted 28,326 stock options and 18,884 Restricted Stock Units (RSUs) on June 20, 2025, though vesting terms reference a June 20, 2024 grant date, creating an inconsistency.

Novavax, Inc. Director Gregg H. Alton acquired 28,326 stock options and 18,884 restricted stock units, which vested on June 20, 2025, as part of his compensation.

Novavax Inc. Director Margaret G. McGlynn reported the acquisition of 28,326 stock options and 18,884 restricted stock units, which vested on June 20, 2025, as part of her compensation.

Novavax Director Margaret G. McGlynn exercised 10,420 restricted stock units, converting them into common stock and increasing her direct beneficial ownership to 25,588 shares.

Novavax Inc. Director Gregg H. Alton has exercised 10,420 Restricted Stock Units, converting them into common stock and increasing his direct beneficial ownership to 28,805 shares.

Novavax Director Rachel K. King reported the exercise of 10,420 Restricted Stock Units and the acquisition of an equal number of common shares, increasing her direct beneficial ownership to 25,190 shares.

Novavax Director Richard J. Rodgers reported the conversion of 10,420 Restricted Stock Units into common stock, increasing his direct beneficial ownership to 24,690 shares.

Novavax Director David M. Mott has filed a Form 4 reporting a pre-scheduled exercise of 10,420 restricted stock units set to occur on June 12, 2025, under a Rule 10b5-1 trading plan.

Novavax Director Richard Douglas exercised 10,420 restricted stock units, converting them into common stock and increasing his direct beneficial ownership to 54,340 shares.

Director Charles W. Newton reports the acquisition of stock options and restricted stock units in Novavax, Inc.

Director John W. Shiver reports the acquisition of stock options and restricted stock units in Novavax, Inc.

John Trizzino, President and COO of Novavax, reports the disposition of shares to cover tax obligations related to the vesting of restricted stock units.

James Patrick Kelly, EVP, CFO and Treasurer of Novavax Inc, reports the vesting and disposal of shares related to restricted stock units.